Chamberlain JS - Search Results

1

Split intein-mediated protein trans-splicing to express large dystrophins.

Tasfaout H, Halbert CL, McMillen TS, Allen JM, Reyes TR, Flint GV, Grimm D, Hauschka SD, Regnier M, Chamberlain JS. Tasfaout H, et al. Among authors: chamberlain js. Nature. 2024 Aug;632(8023):192-200. doi: 10.1038/s41586-024-07710-8. Epub 2024 Jul 17. Nature. 2024. PMID: 39020181 Free PMC article.

2

Systemic delivery of genes to striated muscles using adeno-associated viral vectors.

Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG, Russell DW, Chamberlain JS. Gregorevic P, et al. Among authors: chamberlain js. Nat Med. 2004 Aug;10(8):828-34. doi: 10.1038/nm1085. Epub 2004 Jul 25. Nat Med. 2004. PMID: 15273747 Free PMC article.

3

rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice.

Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haraguchi M, Meuse L, Finn E, Adams ME, Froehner SC, Murry CE, Chamberlain JS. Gregorevic P, et al. Among authors: chamberlain js. Nat Med. 2006 Jul;12(7):787-9. doi: 10.1038/nm1439. Epub 2006 Jul 2. Nat Med. 2006. PMID: 16819550 Free PMC article.

4

Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6.

Odom GL, Gregorevic P, Allen JM, Chamberlain JS. Odom GL, et al. Among authors: chamberlain js. Mol Ther. 2011 Jan;19(1):36-45. doi: 10.1038/mt.2010.205. Epub 2010 Sep 21. Mol Ther. 2011. PMID: 20859263 Free PMC article.

5

Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy.

Bengtsson NE, Hall JK, Odom GL, Phelps MP, Andrus CR, Hawkins RD, Hauschka SD, Chamberlain JR, Chamberlain JS. Bengtsson NE, et al. Among authors: chamberlain js, chamberlain jr. Nat Commun. 2017 Feb 14;8:14454. doi: 10.1038/ncomms14454. Nat Commun. 2017. PMID: 28195574 Free PMC article.

6

AAV6 Vector Production and Purification for Muscle Gene Therapy.

Halbert CL, Allen JM, Chamberlain JS. Halbert CL, et al. Among authors: chamberlain js. Methods Mol Biol. 2018;1687:257-266. doi: 10.1007/978-1-4939-7374-3_18. Methods Mol Biol. 2018. PMID: 29067669

7

Development of Novel Micro-dystrophins with Enhanced Functionality.

Ramos JN, Hollinger K, Bengtsson NE, Allen JM, Hauschka SD, Chamberlain JS. Ramos JN, et al. Among authors: chamberlain js. Mol Ther. 2019 Mar 6;27(3):623-635. doi: 10.1016/j.ymthe.2019.01.002. Epub 2019 Feb 1. Mol Ther. 2019. PMID: 30718090 Free PMC article.

8

Dystrophin Gene-Editing Stability Is Dependent on Dystrophin Levels in Skeletal but Not Cardiac Muscles.

Bengtsson NE, Tasfaout H, Hauschka SD, Chamberlain JS. Bengtsson NE, et al. Among authors: chamberlain js. Mol Ther. 2021 Mar 3;29(3):1070-1085. doi: 10.1016/j.ymthe.2020.11.003. Epub 2020 Nov 5. Mol Ther. 2021. PMID: 33160075 Free PMC article.

9

Comparison of dystrophin expression following gene editing and gene replacement in an aged preclinical DMD animal model.

Bengtsson NE, Crudele JM, Klaiman JM, Halbert CL, Hauschka SD, Chamberlain JS. Bengtsson NE, et al. Among authors: chamberlain js. Mol Ther. 2022 Jun 1;30(6):2176-2185. doi: 10.1016/j.ymthe.2022.02.003. Epub 2022 Feb 8. Mol Ther. 2022. PMID: 35143959 Free PMC article.

10

Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain.

Banks GB, Gregorevic P, Allen JM, Finn EE, Chamberlain JS. Banks GB, et al. Among authors: chamberlain js. Hum Mol Genet. 2007 Sep 1;16(17):2105-13. doi: 10.1093/hmg/ddm158. Epub 2007 Jun 22. Hum Mol Genet. 2007. PMID: 17588958

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

250 results

Search Page